Comparative evaluation of the influence of diabetic retinopathy progression factors on indices of lipid metabolism in metabolic syndrome

Main Article Content

L.Yu. Pуlуpenko
V.М. Serdіuk
O.P. Kucher


Background. The search and study of new risk factors for the development and progression of diabetic retinopathy (DRP) and their modifying influence on the components of metabolic syndrome in type 2 diabetes mellitus (T2DM) remain relevant. The purpose was to conduct a comparative evaluation of the impact of certain DRP development factors on indices of lipid metabolism in metabolic syndrome. Materials and methods. The research was carried out in 64 patients (95 eyes) with T2DM, metabolic syndrome and DRP (males and females, average age 61.55 ± 2.37 years, average duration of diabetes 11.23 ± 2.11 years, average level of HbA1c 9.89 ± 0.78 %, average body mass index 34.55 ± 3.75 kg/m2), who were divided into 3 groups depending on the stage of DRP. Results. Results had showed that the following factors have modifying influence on the level of total cholesterol in the blood of patients with T2DM and DRP: age of patients (under 60 years), duration of diabetes (less than 10 years), decompensation of carbohydrates metabolism — for the 3rd stage of DRP, features of therapy for T2DM (oral hypoglycemic drugs) — for the 2nd stage of DRP; on the level of low-density lipoprotein cholesterol: younger age of patients, decompensation of diabetes — for the 3rd stage of DRP, features of hypoglycemic therapy (insulin therapy), shorter duration of diabetes — for the 2nd stage of DRP; on the level of triglycerides: age of patients (under 60 years), duration of diabetes (less than 10 years) and insulin therapy — for the 1st and 3rd stages of DRP. Conclusions. It is concluded that features of hypoglycemic therapy can be a new modifying factor for the risk of DRP progression.

Article Details

How to Cite
Pуlуpenko L., Serdіuk V., and O. Kucher. “Comparative Evaluation of the Influence of Diabetic Retinopathy Progression Factors on Indices of Lipid Metabolism in Metabolic Syndrome”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 8, Dec. 2017, pp. 563-9, doi:10.22141/2224-0721.13.8.2017.119271.
Clinical Diabetology


Antonetti DA, Klein R, Gardner TW. Diabetic Retinopathy. N Engl J Med. 2012 Mar 29;366(13):1227-39. doi: 10.1056/NEJMra1005073.

Arnold E, Rivera JC, Thebault S, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010 Dec;59(12):3192-7. doi: 10.2337/db10-0873.

VADT Study Group; Azad N, Agrawal L, Emanuele NV, et al. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2014 Feb;37(2):501-506. doi: 10.2337/dc13-1193.

Ning С, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010 Jul 10;376(9735):124-36. doi: 10.1016/S0140-6736(09)62124-3.

Dong L, Bai J, Jiang X, et al. The gene polymorphisms of IL-8(-251T/A) and IP-10(-1596C/T) are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population. Eye (Lond). 2017 Apr;31(4):601-607. doi: 10.1038/eye.2016.287.

Hirsch IB, Brownlee M. Beyond hemoglobin A1c – need for additional markers of risk for diabetic microvascular complications. JAMA. 2010 Jun 9;303(22):2291-2. doi: 10.1001/jama.2010.785.

Hughes JM, Brink A, Witmer AN, Hanraads-de Riemer M, Klaassen I, Schlingemann RO. Vascular leucocyte adhesion molecules unaltered in the human retina in diabetes. Br J Ophthalmol. 2004 Apr; 88(4): 566–572. doi: 10.1136/bjo.2003.021204.

Klein R. The epidemiology of diabetic retinopathy. In: Duh E, editor. Diabetic retinopathy. Totowa, NJ: Humana; 2008. 67-107 p.

Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009 Sep;32(9):1704-9. doi: 10.2337/dc09-0102.

Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010 Jul;53(7):1341-8. doi: 10.1007/s00125-010-1720-1.

West SD, Groves DC, Lipinski HJ, et al. The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. Diabet Med. 2010 Apr;27(4):423-30. doi: 10.1111/j.1464-5491.2010.02962.x.

Zietz B, Buechler C, Kobuch K, Neumeier M, Schölmerich J, Schäffler A. Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2008 Oct;116(9):532-6. doi: 10.1055/s-2008-1058086.

Vytovskaya OP, Axmad TS, Bychkova NG. Violation of the cytokine regulation in patients with diabetic retinopathy. Ukrainian Medical Journal. 2016;6(116):93-95. (in Russian).

Malachkova NV, Komarovska IV, Kirilyuk ML. Blood glucose level and insulin resistance in patients with type 2 diabetic mellitus, diabetic retinopathy and obesity. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(3):129-134. doi: 10.22141/2224-0721.13.3.2017.104108.

Malachkova NV, Kirilyuk ML, Komarovska IV. The features of blood pressure in patients with diabetic retinopathy, type 2 diabetes and adiposity. Arhiv oftalmologii Ukrainy. 2017;5(1(7)):32-37. (in Russian).

Malachkova NV, Kirilyuk ML, Komarovska IV. Association between serum resistin level and diabetic retinopathy in obese patients with type 2 diabetes mellitus. Oftalmologicheskii zhurnal. 2017;4(477):9-13. (in Russian).

Serdyuk VN, Ishhenko VA. The content of leptin in the blood of patients with type 2 diabetes mellitus at different stages of diabetic retinopathy. Oftalmologija. 2017;1(06):46-54. (in Russian).

Serdyuk VN, Ishсhenko VA. Morphometric and biochemical clusters of metabolic syndrome in type 2 diabetic patients at different stages of diabetic retinopathy. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2016;7(79):69-74. doi: 10.22141/2224-0721.7.79.2016.86421.